The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.
Chief R&D and commercial officer Najat Khan, PhD, tells GEN Edge company aims to improve design of studies, accelerate enrollment, and enhance evidence generation.
WALTHAM, Mass. and BOULDER, Colo., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COGT), a biotechnology company focused on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback